Active ETF

Putnam BioRevolution ETF (Class A) (SYNB)

Investing in companies that are leveraging innovation within biology

Putnam active ETFs

Powered by the high-conviction ideas of our active investment teams.

More about active ETFs
Putnam BioRevolution ETF (SYNB)

Harnessing the biorevolution for investors

The revolution in biology and life sciences is unleashing new potential for innovation across many sectors, creating opportunities for investors.

Read more

NAV as of 05/31/23

$26.64

Market data all data below as of 05/31/23

Closing market price $26.67
30-day median bid-ask spread 0.11%
Day high $26.67
Day low $26.67
Premium/Discount 0.11%
30-day average trading volume 172
Net assets and outstanding shares Download CSV

How to buy Putnam ETFs

Putnam ETFs can be purchased and sold the same way you would buy or sell a stock — through most self-directed brokers or with the guidance of your advisor. Opening an online, self-directed brokerage account provides investors with:

  • Accessibility to a variety of investment products
  • Tools to help you build and optimize your portfolio
  • Flexibility and freedom of managing your investment portfolio
Learn about Putnam active ETFs

ETF facts as of 04/30/23

Ticker
SYNB
CUSIP
746729805
Inception date
09/29/22
Total net assets
$4.80M
Total expense ratio
0.70%
Open to new investors
Category
Blend
Turnover (fiscal year-end)
--
Dividend frequency
Annually
Number of holdings
45
Fiscal year-end
April

Objective

Putnam BioRevolution ETF seeks long term capital appreciation.

Strategy and process

  • Pursues transformative growth across sectorsThe economic impact of the biology revolution is spreading beyond health care, with potential to transform multiple sectors and drive investment opportunities.
  • Collaborative research processA benchmark-agnostic approach leverages unique, integrated insights of Putnam sector analysts and the Sustainable Equity team.
  • Concentrated portfolioThe manager seeks outperformance by investing in 30-50 high-conviction stocks selected through disciplined portfolio construction and risk management.

Management team

William C. Rives, CFA

Portfolio Manager, Analyst

10 years in industry

10 years at Putnam Investments

See full profile

Literature

Fund information
Fact Sheet (PDF)

Legal documents
Summary Prospectus (PDF)
Statutory Prospectus (PDF)
Statement of Additional Information (SAI) (PDF)
Semiannual Report (PDF)

Related/Investment insights

What is the biorevolution?
The revolution in biology and life sciences is unleashing new potential for innovation across many sectors, creating opportunities for investors.
Economic moats | Active investors seek wider moats
Economic moats, also called business moats, are competitive advantages that help a company maintain long-term profits and market share over competitors.
How an active core strategy can benefit equity investors
An active core strategy backed by fundamental, sector-based research has demonstrated impressive long-term performance versus passive strategies.

Performance

  • Total return (%) as of 03/31/23

Cumulative Total return (%) as of 03/31/23

Cumulative performance 1 yr. 3 yrs. 5 yrs. Life
Net asset value -- -- -- 9.18%
Market price -- -- -- 9.10%

Current performance may be lower or higher than the quoted past performance, which cannot guarantee future results. Share price, principal value, and return will vary, and you may have a gain or loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. Returns for periods of less than one year are not annualized. Market performance is determined using the bid/ask midpoint at 4:00 p.m. Eastern time. Market performance does not represent the returns you would receive if you traded shares at other times throughout the day.

Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV, and are not individually redeemed from the fund. Brokerage commissions will reduce returns.

The fund has limited public trading history.

 

Performance snapshot

  Net asset value Market price
1 mt. as of 05/31/23 -2.94% -2.73%
YTD as of 05/31/23 2.65% 2.68%

Historical premium/discount

Number of days at premium --
Number of days at NAV --
Number of days at discount --

Compare

See how this fund stacks up against its peers with FundVisualizer®

— or —

New to FundVisualizer? Watch tutorials on how to get started.

Fund and portfolio analysis for free, anytime, anywhere
Import your fund data into FundVisualizer
Create hypotheticals with FundVisualizer

For more tutorials, please visit fundvisualizer.com

** FundVisualizer comparison based on Putnam fund versus the largest fund in its Morningstar category.

Holdings

Portfolio holdings

Full portfolio holdings Download XLSX
Bio-Rad Laboratories 6.88%
Thermo Fisher Scientific 6.50%
Alphabet 5.19%
Eli Lilly 4.12%
Nvidia Corp 3.92%
Novozymes A/S - B Shares 3.88%
Ingevity Corp 3.70%
Lululemon Athletica 3.65%
Corteva 3.64%
Dupont De Nemours 3.33%
Top 10 holdings, percent of portfolio 44.82%

Sector weightings as of 04/30/23

Health care 53.14%
Materials 21.66%
Consumer discretionary 6.84%
Consumer staples 5.47%
Communication services 5.19%
Information technology 3.92%
Cash and net other assets 3.79%

Sectors will vary over time.

Equity statistics as of 04/30/23

Median market cap $24.73B
Weighted average market cap $177.99B
Price to book 3.46
Price to earnings 32.79

The S&P 500® Index is an unmanaged index of common stock performance. You cannot invest directly in an index.

Consider these risks before investing: Biology revolution companies face intense competition and potentially rapid product obsolescence. Biology revolution companies may be adversely affected by the loss or impairment of intellectual property rights and other proprietary information or changes in government regulations. The potential for an increased amount of required disclosure or lack of access to proprietary scientific information could negatively impact the performance of these companies. Investments in small and/or midsize companies increase the risk of greater price fluctuations. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. The value of investments in the fund's portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general economic, political, or financial market conditions; investor sentiment and market perceptions; government actions; geopolitical events or changes; and factors related to a specific issuer, geography, industry, or sector. These and other factors may lead to increased volatility and reduced liquidity in the fund's portfolio holdings. As a non-diversified fund, the fund invests in fewer issuers and is more vulnerable than a more broadly diversified fund to fluctuations in the values of the securities it holds. Our investment techniques, analyses, and judgments may not produce the outcome we intend. The investments we select for the fund may not perform as well as other securities that we do not select for the fund. We, or the fund's other service providers, may experience disruptions or operating errors that could have a negative effect on the fund. You can lose money by investing in the fund.